3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects

@article{Vry200432Cyano3trifluoromethylphenoxyphenyl44,
  title={3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects},
  author={J. de Vry and D. Denzer and E. Reissmueller and Maud Eijckenboom and M. Heil and H. Meier and F. Mauler},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2004},
  volume={310},
  pages={620 - 632}
}
  • J. de Vry, D. Denzer, +4 authors F. Mauler
  • Published 2004
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
  • 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074) is a novel, selective cannabinoid CB1/CB2 receptor ligand (Ki = 55.4, 48.3, and 45.5 nM at rat and human cannabinoid CB1 and human CB2 receptors, respectively), with partial agonist properties at these receptors in guanosine 5-[γ35S]-thiophosphate triethyl-ammonium salt ([35S]GTPγS) binding assays. In rats, generalization of BAY 59-3074 to the cue induced by the cannabinoid CB1 receptor agonist (–)-(R… CONTINUE READING
    56 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.  
    ConditionsDiabetic Peripheral Neuropathic Pain
    InterventionDrug
    Interventional Clinical Trial
    Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.  
    ConditionsDiabetic Neuropathies
    InterventionDrug
    Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA
    • 35
    • PDF
    Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.
    • 11
    (-)-Trans-Δ9-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users.
    • Takato Hiranita
    • Chemistry, Medicine
    • Journal of alcoholism and drug dependence
    • 2016
    • 4
    • PDF
    Actions of N-arachidonyl-glycine in a rat neuropathic pain model
    • 65

    References

    SHOWING 1-10 OF 46 REFERENCES
    Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.
    • 95
    • PDF
    delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.
    • 55
    Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist.
    • 12
    Large receptor reserve for cannabinoid actions in the central nervous system.
    • 107
    • PDF
    Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
    • 368
    Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm
    • 29
    CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
    • 204
    Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats
    • 122